Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas juin 28, 20230CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC juin 23, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas juin 22, 20230CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC juin 16, 20230CommentsEN NL Read More
Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC juin 15, 20230CommentsEN Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas juin 15, 20230CommentsEN NL Read More
Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema juin 12, 20230CommentsEN Read More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC juin 12, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS juin 9, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS juin 6, 20230CommentsEN NL Read More
Oxurion Announces Results of the Extraordinary Shareholders’ Meeting of 22 May 2023 juin 5, 20230CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC juin 1, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS mai 31, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS mai 26, 20230CommentsEN NL Read More
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema mai 25, 20230CommentsEN Read More
